[ad_1]
Rubicon Analysis Restricted, established in 1999, is a pharmaceutical formulation firm centered on innovation by means of analysis and improvement, with a robust presence in regulated markets, significantly the US.
The corporate operates two R&D services inspected by the USFDA (United States Meals and Drug Administration) in India and Canada, together with two manufacturing vegetation in India. It holds accreditations from world regulatory our bodies just like the USFDA, WHO-GMP (World Well being Group – Good Manufacturing Practices), and Well being Canada. Rubicon’s portfolio consists of 55 commercialised formulations within the U.S., highlighting its deal with regulated markets.
Challenge dimension
Funds to be Raised within the IPO
Quantity
General
₹1,085 crores
Contemporary Challenge
₹500 crores
Provide on the market
₹585 crores
The utilisation of proceeds:
Goal
INR crores (%)
Compensation of Borrowings
310.00 (62.00%)
Funding acquisitions and common company functions
190.00 (38.00%)
Monetary Snapshot
Monetary Yr Ended
March 2022
March 2023
March 2024
Complete Belongings
559.52
749.70
1,109.49
Income
330.42
419.00
872.39
Revenue After Tax
(67.12)
(16.89)
91.01
*All figures are in ₹ Crores.
Strengths
Holds a robust portfolio of commercialised merchandise, sustaining a market share of over 25% for seven merchandise within the US market.
R&D capabilities in India and Canada allow product innovation and improvement, lowering reliance on third events.
Established US gross sales and distribution platform by means of subsidiaries, protecting each non-branded and branded product markets.
Demonstrates regulatory compliance with US FDA inspections and approvals from worldwide our bodies.
Danger components
The corporate closely depends on the US market, making it weak to antagonistic developments in that area.
Working in a extremely regulated business, any product recollects, inspection failures or facility shutdowns may negatively affect operations.
R&D efforts could not all the time result in profitable marketable merchandise, posing dangers to income development.
Intense competitors inside the pharmaceutical business could have an effect on margins and hinder future development prospects.
Fluctuations in overseas foreign money change charges may negatively affect the corporate’s monetary efficiency.
Debt agreements, together with unsecured loans, impose restrictive covenants, and any non-compliance may result in accelerated reimbursement obligations.
Tell us what you consider this upcoming IPO within the feedback under.
[ad_2]
Source link
